Literature DB >> 3496958

Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells.

S L Marcus, J P Dutcher, E Paietta, N Ciobanu, J Strauman, P H Wiernik, S H Hutner, O Frank, H Baker.   

Abstract

Adoptive immunotherapy of human cancer was investigated in our institution as part of a National Cancer Institute extramural group study. This treatment, for patients with metastatic malignant melanoma, hypernephroma, and colon carcinoma, consisted of three phases: (a) 5 days of i.v. high-dose (10(5) units/kg every 8 h) interleukin 2, (b) 6 1/2 days of rest plus leukapheresis; and (c) 4 days of high-dose interleukin 2 plus three infusions of autologous lymphokine-activated killer cells. Toxicities included fever, chills, tachycardia, hypotension, vomiting, diarrhea, and fluid retention. Ascorbic acid is known to be important to cell-mediated immunity, and it has been reported to be depleted during physiologically stressful events. Therefore, we determined plasma ascorbic acid levels in patients (n = 11) before adoptive immunotherapy and before and after Phases 1, 2, and 3 of treatment. Patients entering the trial were not malnourished. Mean plasma ascorbic acid levels were normal (0.64 +/- 0.25 mg/dl) before therapy. Mean levels dropped by 80% after the first phase of treatment with high-dose interleukin 2 alone (0.13 +/- 0.08 mg/dl). Mean plasma ascorbic acid levels remained severely depleted (0.08 to 0.13 mg/dl) throughout the remainder of the treatment, becoming undetectable (less than 0.05 mg/dl) in eight of 11 patients during this time. Values obtained from 24-h urine collections on two of two patients indicated that ascorbate was not excreted in the urine. Plasma ascorbic acid normalized in three of three patients tested 1 mo after the completion of treatment. Unlike the results for ascorbic acid, blood pantothenate and plasma vitamin E remained within normal limits in all 11 patients throughout the phases of therapy. Responders (n = 3) differed from nonresponders (n = 8) in that plasma ascorbate levels in the former recovered to at least 0.1 mg/dl (frank clinical scurvy) during Phases 2 and 3, whereas levels in the latter fell below this level.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3496958

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Multiple organ dysfunction dramatically improving with the infusion of vitamin C: more support for the persistence of scurvy in our "welfare" society.

Authors:  P Kieffer; P Thannberger; J M Wilhelm; C Kieffer; F Schneider
Journal:  Intensive Care Med       Date:  2001-02       Impact factor: 17.440

Review 2.  Vitamins C and E: beneficial effects from a mechanistic perspective.

Authors:  Maret G Traber; Jan F Stevens
Journal:  Free Radic Biol Med       Date:  2011-05-25       Impact factor: 7.376

Review 3.  Clinical toxicity of interleukin-2.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1992 Nov-Dec       Impact factor: 5.606

Review 4.  The role of vitamin C in the treatment of pain: new insights.

Authors:  Anitra C Carr; Cate McCall
Journal:  J Transl Med       Date:  2017-04-14       Impact factor: 5.531

5.  The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) Protocol: a prospective, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial.

Authors:  David N Hager; Michael H Hooper; Gordon R Bernard; Laurence W Busse; E Wesley Ely; Alpha A Fowler; David F Gaieski; Alex Hall; Jeremiah S Hinson; James C Jackson; Gabor D Kelen; Mark Levine; Christopher J Lindsell; Richard E Malone; Anna McGlothlin; Richard E Rothman; Kert Viele; David W Wright; Jonathan E Sevransky; Greg S Martin
Journal:  Trials       Date:  2019-04-05       Impact factor: 2.279

Review 6.  Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy.

Authors:  Samuel C Wagner; Boris Markosian; Naseem Ajili; Brandon R Dolan; Andy J Kim; Doru T Alexandrescu; Constantin A Dasanu; Boris Minev; James Koropatnick; Francesco M Marincola; Neil H Riordan
Journal:  J Transl Med       Date:  2014-05-13       Impact factor: 5.531

7.  Low Vitamin C Status in Patients with Cancer Is Associated with Patient and Tumor Characteristics.

Authors:  Rebecca White; Maria Nonis; John F Pearson; Eleanor Burgess; Helen R Morrin; Juliet M Pullar; Emma Spencer; Margreet C M Vissers; Bridget A Robinson; Gabi U Dachs
Journal:  Nutrients       Date:  2020-08-05       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.